Concomitant diagnosis of endometrial and breast cancer - does the sequence matters?

Tomer Stern*, Shira Peleg Hasson, Akram Saad, Keren Levanon, Nadav Michaan, Ido Laskov, Ido Wolf, Dan Grisaru, Tamar Safra

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To examine whether patients with both breast cancer (BC) and endometrial cancer (EC) have different features of disease, and whether the sequence of appearance of these tumors is correlated with a more aggressive course. Methods: A retrospective, multi-center observational cohort study of patients treated in two tertiary medical centers between 2014 and 2020. Files of patients who had a co-diagnosis of BC and EC were reviewed and clinical, epidemiological, pathological and genetic characteristics were collected. Results: 67 patients with a co-diagnosis of both malignances were divided into two groups according to primary tumor diagnosis: BC first group (43/67, 64%) and EC first group (24/67, 36%). The time interval between diagnosis of malignancies was significantly longer in the BC first group (mean 144.5 months vs. 67 months, p < 0.05). BRCA mutations were found in higher numbers in the BC first group (27.5% vs. 9.5%, p = 0.18). A significantly higher number of patients in the BC first group had uterine serous carcinoma (USC) histology (44% vs. 12.5%, p < 0.05). This was independent of tamoxifen usage among patients (OR 0.65, 95% CI 0.17–2.49). Conclusions: In patients suffering from both BC and EC, the sequence of occurrence of malignancies has relevance: When EC presents as a second primary tumor, it tends to present in a more aggressive form, independent of previous tamoxifen use. The time interval between the diagnosis of malignancies was significantly longer in this group, offering an opportunity to improve preventive measures to decrease the likelihood of a subsequent lethal second cancer.

Original languageEnglish
Article number100863
JournalGynecologic Oncology Reports
Volume38
DOIs
StatePublished - Nov 2021

Keywords

  • BRCA
  • Breast Cancer
  • Endometrial Cancer
  • Tamoxifen
  • Uterine serous carcinoma

Fingerprint

Dive into the research topics of 'Concomitant diagnosis of endometrial and breast cancer - does the sequence matters?'. Together they form a unique fingerprint.

Cite this